MMPs As Therapeutic Targets--still a Viable Option?

Overview

Journal Semin Cell Dev Biol

Specialties Cell Biology
Reproductive Medicine

Date 2007 Aug 19

PMID 17693104

Citations 126

Authors

Barbara Fingleton

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinases (MMPs) appear to be ideal drug targets--they are disease-associated, extracellular enzymes with a dependence on zinc for activity. This apparently straightforward target, however, is much more complex than initially realized. Although disease associated, the roles for particular enzymes may be healing rather than harmful making broad-spectrum inhibition unwise; targeting the catalytic zinc with specificity is difficult, since other related proteases as well as non-related proteins can be affected by some chelating groups. While the failure of early-generation MMP inhibitors dampened enthusiasm for this type of drug, there has recently been a wealth of studies examining the basic biology of MMPs which will greatly inform new drug trials in this field.

Citing Articles

Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma.

Szczygielski O, Dabrowska E, Niemyjska S, Przylipiak A, Zajkowska M Int J Mol Sci. 2025; 25(24.

PMID: 39769318 PMC: 11676509. DOI: 10.3390/ijms252413558.

The TIMP protein family: diverse roles in pathophysiology.

Coates-Park S, Rich J, Stetler-Stevenson W, Peeney D Am J Physiol Cell Physiol. 2024; 326(3):C917-C934.

PMID: 38284123 PMC: 11193487. DOI: 10.1152/ajpcell.00699.2023.

New Derivatives of Hydroxybutanamide: Preparation, MMP Inhibition, Cytotoxicity, and Antitumor Activity.

Balakina A, Gadomsky S, Kokovina T, Sashenkova T, Mishchenko D, Terentiev A Int J Mol Sci. 2023; 24(22).

PMID: 38003553 PMC: 10671431. DOI: 10.3390/ijms242216360.

Engineering minimal tissue inhibitors of metalloproteinase targeting MMPs via gene shuffling and yeast surface display.

Hosseini A, Kumar S, Hedin K, Raeeszadeh-Sarmazdeh M Protein Sci. 2023; 32(12):e4795.

PMID: 37807423 PMC: 10659938. DOI: 10.1002/pro.4795.

Breaching the Fortress of Tumor Microenvironment to Control Cancer Metastasis.

Jaguri A, Ahmad A Cancers (Basel). 2023; 15(18).

PMID: 37760530 PMC: 10526375. DOI: 10.3390/cancers15184562.

References

Fingleton B . Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci. 2005; 11:479-91. DOI: 10.2741/1811. View

Burrage P, Mix K, Brinckerhoff C . Matrix metalloproteinases: role in arthritis. Front Biosci. 2005; 11:529-43. DOI: 10.2741/1817. View

Hartenstein B, Dittrich B, Stickens D, Heyer B, Vu T, Teurich S . Epidermal development and wound healing in matrix metalloproteinase 13-deficient mice. J Invest Dermatol. 2005; 126(2):486-96. PMC: 2767339. DOI: 10.1038/sj.jid.5700084. View

Thomas Peterson J . The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res. 2006; 69(3):677-87. DOI: 10.1016/j.cardiores.2005.11.032. View

Janssens S, Lijnen H . What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?. Cardiovasc Res. 2006; 69(3):585-94. DOI: 10.1016/j.cardiores.2005.12.010. View

Demacq C, de Souza A, Machado A, Gerlach R, Tanus-Santos J . Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta. 2005; 365(1-2):183-7. DOI: 10.1016/j.cca.2005.08.017. View

Lara Jr P, Stadler W, Longmate J, Quinn D, Wexler J, van Loan M . A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006; 12(5):1556-63. DOI: 10.1158/1078-0432.CCR-05-2074. View

Overall C, Kleifeld O . Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer. 2006; 94(7):941-6. PMC: 2361222. DOI: 10.1038/sj.bjc.6603043. View

Zeisberg M, Khurana M, Rao V, Cosgrove D, Rougier J, Werner M . Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med. 2006; 3(4):e100. PMC: 1391977. DOI: 10.1371/journal.pmed.0030100. View

10.

Deryugina E, Quigley J . Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006; 25(1):9-34. DOI: 10.1007/s10555-006-7886-9. View

11.

Pardo A, Selman M . Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc. 2006; 3(4):383-8. DOI: 10.1513/pats.200601-012TK. View

12.

Houghton A, Grisolano J, Baumann M, Kobayashi D, Hautamaki R, Nehring L . Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 2006; 66(12):6149-55. DOI: 10.1158/0008-5472.CAN-04-0297. View

13.

Acuff H, Sinnamon M, Fingleton B, Boone B, Levy S, Chen X . Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res. 2006; 66(16):7968-75. DOI: 10.1158/0008-5472.CAN-05-4279. View

14.

Shitara Y, Sugiyama Y . Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006; 112(1):71-105. DOI: 10.1016/j.pharmthera.2006.03.003. View

15.

Yasuda S, Miyazaki S, Kinoshita H, Nagaya N, Kanda M, Goto Y . Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction. Clin Sci (Lond). 2006; 112(1):43-9. DOI: 10.1042/CS20060110. View

16.

Corry D, Rishi K, Kanellis J, Kiss A, Xu J, Feng L . Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol. 2002; 3(4):347-53. PMC: 2814346. DOI: 10.1038/ni773. View

17.

Coussens L, Fingleton B, Matrisian L . Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002; 295(5564):2387-92. DOI: 10.1126/science.1067100. View

18.

Egeblad M, Werb Z . New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2(3):161-74. DOI: 10.1038/nrc745. View

19.

Li C, Cantor W, Nili N, Robinson R, Fenkell L, Tran Y . Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol. 2002; 39(11):1852-8. DOI: 10.1016/s0735-1097(02)01873-9. View

20.

Galis Z, Johnson C, Godin D, Magid R, Shipley J, Senior R . Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002; 91(9):852-9. DOI: 10.1161/01.res.0000041036.86977.14. View